Iso-osmolar contrast agents in chronic kidney disease: what is true?

• A. Iso-osmolar contrast agents reduce nephrotoxicity compared with conventional contrast.
• B. Iso-osmolar contrast agents worsen nephrotoxicity.
• C. They have no impact on kidney risk.
• D. They are contraindicated in CKD.

Answer: (A)

Iso-osmolar contrast media are designed to minimize renal stress by having an osmolality similar to plasma. In CKD, the kidney is already vulnerable to injury from contrast exposure, and high-osmolality agents can worsen renal vasoconstriction and tubular damage. By matching plasma osmolality, iso-osmolar agents produce less osmotic load and less medullary hypoxia, which translates into a lower risk of contrast-associated kidney injury in many patients, especially those with preexisting kidney disease or diabetes. Large studies and reviews have shown a tendency toward reduced nephrotoxicity with iso-osmolar agents compared with conventional contrast in CKD, though the benefit is not absolute and depends on factors like hydration, contrast volume, and patient risk. Consequently, the statement that iso-osmolar contrast agents reduce nephrotoxicity compared with conventional contrast is the best-supported choice. They are not contraindicated in CKD, and they do have an impact on kidney risk, though no method eliminates risk entirely.